Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

AstraZeneca Announced Enhertu Recommended for Approval in the EU by CHMP for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen

By Charles Gross
Today, 4:18 PM
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

AZN

Read More
2 minute read

Biocartis Group Announced New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso

By Charles Gross
Today, 4:18 PM
Biocartis Group NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) aimed at the development and applicable pre-market notification or approval with the US FDA of a novel companion diagnostic1 (CDx) test on Biocartis' molecular rapid and easy-to-use di

AZN

Read More
4 minute read

AstraZeneca Announced CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial in Data Presented at ASCO

By Charles Gross
Today, 4:18 PM
Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's CALQUENCE®(acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known profile for CALQUENCE at a median follow up of approximately five years in combination and as a monotherapy in chronic l

AZN